Revisiting chemoresistance in ovarian cancer: Mechanism, biomarkers, and precision medicine

作者：Guo, Chong; Song, Chaoying; Zhang, Jiali; Gao, Yisong; Qi, Yuying; Zhao, Zongyao; Yuan, Chengfu^*

来源：Genes & Diseases, 2022, 9(3): 668-681.

DOI：10.1016/j.gendis.2020.11.017

• Clinical outcomes
• Mechanisms
• Molecular biomarkers
• Ovarian cancer
• Platinum resistance

Among the gynecological cancers, ovarian cancer is the most lethal. Its therapeutic options include a combination of chemotherapy with platinum-based compounds and cytoreductive surgery. Most ovarian cancer patients exhibit an initial response to platinum-based therapy, however, platinum resistance has led to up to 80% of this responsive cohort becoming refractory. Ovarian cancer recurrence and drug resistance to current chemotherapeutic options is a global challenge. Chemo-resistance is a complex phenomenon that involves multiple genes and signal transduction pathways. Therefore, it is important to elucidate on the underlying molecular mechanisms involved in chemo-resistance. This inform decisions regarding therapeutic management and help in the identification of novel and effective drug targets. Studies have documented the individual biomarkers of platinum-resistance in ovarian cancer that are potential therapeutic targets. This review summarizes the molecular mechanisms of platinum resistance in ovarian cancer, novel drug targets, and clinical outcomes.